Illumina and Epidarex Capital invest in po...Illumina has opened its first accelerator outside the US in Cambridge to fund genomics start-ups. Meanwhile, Epidarex Capital has raised £102m for UK biotechs. more ➔
Novel adjuvant teases T cells to respond t... Researchers from Italy, Denmark and the UK have devised a new vaccination strategy to tackle hepatitis C and boosting the required strong T cell response. more ➔
First drug found to reduce COVID-19-mortal...A clinical trial has identified the first immuno-modulatory drug to significantly reduce COVID-19 mortality in ventilated patients. more ➔
Germany puts €300m in CureVac AG for COV...In the race aimed at securing access to COVID-19 vaccines, Germany has acquired a minority stake in the local mRNA vaccine producer Curevac AG. more ➔
Abbvie and Genmab team up in oncologyAbbVie is partnering with Genmab A/S to commercialise up to seven new antibody formats. more ➔
Evox Therapeutics signs US$1.2bn deal with...Evox Therapeutics Ltd has licenced its exosome-based RNAi/antisense RNA delivery technology to Eli Lilly to target selected neurological diseases. more ➔
Calliditas Therapeutics raise US$90m in Na...Swedish budenoside formulation specialist Calliditas Therapeutics AB has successfully raised US$90m in an oversubscribed NASDAQ IPO. more ➔
Hyloris Pharmaceuticals prepared to go pub...Belgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels. more ➔
NodThera bags US$55m in Series B roundNodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement. more ➔
Bacterial colonisation differs by tumour t...An analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities. more ➔